HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N R Jørgensen Selected Research

Osteoporosis

10/2022Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
1/2021A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (ß-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM).
12/2019Fracture-induced changes in biomarkers CTX, PINP, OC, and BAP-a systematic review.
9/2019The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial.
5/2019Bone turnover markers are differentially affected by pre-analytical handling.
12/2017The role of the P2X7 receptor on bone loss in a mouse model of inflammation-mediated osteoporosis.
4/2013Association of P2X7 receptor polymorphisms with bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients.
3/2013Functional polymorphisms in the P2X7 receptor gene are associated with osteoporosis.
7/2010Parathyroid hormone and bone healing.
1/2007The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


N R Jørgensen Research Topics

Disease

10Osteoporosis
10/2022 - 01/2007
2Cardiovascular Diseases (Cardiovascular Disease)
09/2019 - 05/2016
1Testicular Neoplasms (Testicular Cancer)
07/2023
1Bone Resorption
01/2021
1Vascular Calcification
09/2020
1Postmenopausal Osteoporosis
09/2019
1Inflammation (Inflammations)
12/2017
1Myocardial Infarction
05/2016
1Prostatic Neoplasms (Prostate Cancer)
04/2016
1Multiple Myeloma
01/2015
1Bone Diseases (Bone Disease)
01/2015
1Acute Coronary Syndrome
10/2012
1Osteoporotic Fractures
10/2012
1Coronary Artery Disease (Coronary Atherosclerosis)
10/2012
1Malnutrition (Nutritional Deficiencies)
07/2010
1Chronic Obstructive Pulmonary Disease (COPD)
01/2007
1Metabolic Bone Diseases (Osteopenia)
01/2007
1Cough
01/2007
1Dyspnea (Shortness of Breath)
01/2007

Drug/Important Bio-Agent (IBA)

4Biomarkers (Surrogate Marker)IBA
09/2020 - 05/2016
4Purinergic P2X7 ReceptorsIBA
12/2017 - 03/2013
2collagen type I trimeric cross-linked peptideIBA
10/2022 - 01/2021
2Edetic Acid (EDTA)FDA Link
01/2021 - 05/2019
2Parathyroid Hormone (Parathormone)IBA
09/2019 - 07/2010
2GlucocorticoidsIBA
12/2017 - 01/2007
1Testosterone (Sustanon)FDA Link
07/2023
1Hormones (Hormone)IBA
07/2023
1Collagen Type I (Type I Collagen)IBA
10/2022
1Procollagen Type IIBA
10/2022
1Vitamin KFDA Link
09/2020
1Teriparatide (Parathar)FDA Link
09/2019
1Heparin (Liquaemin)FDA LinkGeneric
05/2019
1LithiumIBA
05/2019
1Urokinase Plasminogen Activator ReceptorsIBA
05/2016
1AndrogensIBA
04/2016
1Clopidogrel (Plavix)FDA Link
10/2012
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
10/2012
1Estrogens (Estrogen)FDA Link
07/2010
1prednylidene (Pred)IBA
01/2007

Therapy/Procedure

3Therapeutics
07/2023 - 04/2016
1Percutaneous Coronary Intervention
10/2012
1Duration of Therapy
10/2012